Cancer Treatment Results  Survival Rates Cancer Treatments / Therapy Results

Click here to go back to your search results.

Melanoma treatment details. Biologic therapy. University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania, United States

Survival: 10.0 months
Toxicity Grade: 5
Treatments: Biologic therapy
Country: United States
City/State/Province: Pittsburgh, Pennsylvania
Hospital: University of Pittsburgh Cancer Institute
Journal: Link
Date: 2/2010

This phase II study involved 251 patients with relapsed or refractory melanoma. The median age was 53 years and 60% were male.

Patients were treated with the biologic therapy agent tremelimumab, which is a monoclonal antibody that binds to a protein called CTLA-4 and helps the immune system attack tumor cells.

There were two treatment-related deaths due to sudden death and diverticular perforation. Grade 3/4 diarrhea, fatigue, and colitis were also reported.

The median overall survival was 10.0 months.

This study was supported by the pharmaceutical company Pfizer, makers of Tremelimumab.

Correspondence: Dr. John M. Kirkwood; email:

E-mail to a Friend Email Physician More Information